As part of a £10.5 million investment to life sciences, BioClavis have announced they will be creating a base in the Queen Elizabeth University Hospital in Glasgow. A research and development grant of £4.5million has been provided by Scottish Enterprise to the firm to work in collaboration with the NHS and university researchers. BioClavis is a spin-out from molecular profiling company BioSpyder. The grant money...
The EY’s Scotland Attractiveness Survey 2017 highlighted key sectors Scotland is excelling in making it a desirable location to invest and grow in. Scotland has attracted more Research and Development projects than anywhere else in the UK. Life Sciences in Scotland is advancing by showcasing the established university and business community as a market leader across Europe attracting new research and development projecta. To watch...
A global group of laboratories present in more than 40 countries has today unveiled a new facility in Livingston, set to be one of the largest of its kind in the UK, and after investment of £4 million. Bioanalytical testing specialist Eurofins Scientific has revealed the pharmaceutical chemistry, microbiology and water microbiology site after moving from Newbridge. It said the move provides greater capacity for...
Merck, a life science facility in Irvine has had a £1.3million expansion. The expansion allows Merck to now supply materials for cutting edge medicines tackling diseases including Alzheimer’s, rheumatoid arthritis, cancer, flu, diabetes and dementia medicines. The facility produces both liquid and powder cell culture media which is of vital importance to their global network. To read the full article, click here.
Hans Möller has been appointed as new Director of Edinburgh BioQuarter. Formerly Chief Executive of Scandinavia’s largest science park, Hans will take up his new position in October 2017. Read more about this appointment on Edinburgh BioQuarter’s website.
Pharmaceutical giant GSK has unveiled its £44 million vaccine production facility in Montrose. The site, which will produce ingredients for vaccines to treat conditions such as tetanus, pneumonia and whooping cough, has been five years in the making. GSK had first announced plans for its facility, which is now being commissioned, in 2012. The facility will create a further 19 skilled jobs in Montrose by...